Alaunos Therapeutics Inc

CEO Weis Holger’s May 2026 share purchase at $2.37 shows strong insider confidence in Alaunos Therapeutics’ metabolic therapy pipeline and potential undervaluation, but investors should weigh the speculative biotech risks.

Insider buying shows confidence in Alaunos Therapeutics’ T‑cell therapy, even as the stock hits a 52‑week low – a potential sign of future upside.